Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Journal of Gastroenterology

Volumn 53, Issue 4, 2018, Pages 557-565

  Chayama, Kazuaki ^a   Suzuki, Fumitaka ^b   Karino, Yoshiyasu ^c   Kawakami, Yoshiiku ^a   Sato, Ken ^d   Atarashi, Tomofumi ^e   Naganuma, Atsushi ^f   Watanabe, Tsunamasa ^g   Eguchi, Yuichiro ^h   Yoshiji, Hitoshi ⁱ   Seike, Masataka ^j   Takei, Yoshiyuki ^k   Kato, Koji ^l   Alves, Katia ^l   Burroughs, Margaret ^l   Redman, Rebecca ^l   Pugatch, David L ^l   Pilot Matias, Tami J ^l   Krishnan, Preethi ^l   Oberoi, Rajneet K ^l   Xie, Wangang ^l   Kumada, Hiromitsu ^b   more..

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c Sapporo Kosei General Hospital   (Japan)

^d GUNMA UNIVERSITY HOSPITAL   (Japan)

^e Department of Anesthesia   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION TAKASAKI GENERAL MEDICAL CENTER   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAGA UNIVERSITY HOSPITAL   (Japan)

ⁱ NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^j OITA UNIVERSITY HOSPITAL   (Japan)

^k MIE UNIVERSITY HOSPITAL   (Japan)

^l ABBVIE INC   (United States)

more..

Author keywords

Direct acting antivirals; Glecaprevir pibrentasvir; Hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM CHANNEL BLOCKING AGENT; GLECAPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; HEMOGLOBIN; NONSTRUCTURAL PROTEIN 5A; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; SERUM ALBUMIN; VIRUS RNA; ABT-267; ABT-450; ABT-493; ANILIDE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; NS-5 PROTEIN, HEPATITIS C VIRUS; PIBRENTASVIR; QUINOXALINE DERIVATIVE; RITONAVIR; SULFONAMIDE; VIRAL PROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL THERAPY; ARTICLE; ATRIAL FIBRILLATION; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; COMBINATION DRUG THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FEVER; FOLLOW UP; HEAD AND NECK DISEASE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); LIMIT OF QUANTITATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PLATELET COUNT; PRIORITY JOURNAL; PRURITUS; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; ULTRASOUND; VERY ELDERLY; YOUNG ADULT; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; ISOLATION AND PURIFICATION; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANILIDES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; QUINOXALINES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85029796332     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-017-1391-5     Document Type: Article

References (19)

1. Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan. South Korea and Taiwan. Hepatol Int. 2015;9(3):378–90.
2. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61–80.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.
4. Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health. 2012;15(1 Suppl):S65–71.
5. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24(3):336–45.
6. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–72.
7. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1–16.
8. Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48(1):1–12.
9. Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62(4):1037–46.
10. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–53.
11. JSH HCV Treatment Guidelines (2017).
12. Asahina Y, Izumi N, Hiromitsu K, et al. JSH Guidelines for the Management of Hepatitis C Virus Infection: a 2016 update for genotype 1 and 2. Hepatol Res. 2016;46(2):129–65.
13. Viekirax tablets [package insert]. Tokyo, Japan: AbbVie Ltd; 2016.
14. Harvoni tablets [package insert]. Tokyo, Japan: Gilead Sciences; 2016.
15. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006;43(1):54–63.
16. Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;. doi:10.1128/AAC.02558-16.
17. Gane E, Poordad F, Wang S, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016;151(4):651–9 e1.
18. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263–71.
19. Puoti M, Foster GR, Wang S, et al. High SVR rates with eight and twelve weeks of Pangenotypic Glecaprevir/Pibrentasvir: integrated efficacy analysis of genotype 1-6 patients without Cirrhosis. European Association for the Study of the Liver: Amsterdam, Netherlands; 2017.